Skip to main content

Table 3 Clinical biomarkers and CMR parameters at baseline and follow-up among IIM patients with CMR follow-up

From: Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in myocardial and skeletal muscles in idiopathic inflammatory cardiomyopathy

 Baseline (n = 28)Follow-up (n = 28)P* value
Biomarker
 Hct0.40 ± 0.050.43 ± 0.040.005
 CRP (mg/L)5.7 (2.8–17.9)2.2 (1.8–4.1)0.024
 ESR (mm/h)26 (23–47)22 (5–33)0.064
 CK (U/L)479 (83–1060)106 (75–148)0.038
 CK-MB (ng/mL)24.7 (7.1–74.6)2.5 (1.0–4.8)< 0.001
 cTnT (g/L)102 (60–480)17 (10–67)< 0.001
 BNP (pg/mL)235 (72–1184)50 (26–109)0.007
Structural and function
 LVEDVi, ml3/m283.7 ± 19.482.3 ± 18.00.703
 LVESVi, ml3/m234.0 ± 15.334.3 ± 13.80.549
 LVmassi, g/m251.2 ± 12.545.2 ± 10.20.011
 LVEF, %59.4 ± 8.760.5 ± 10.50.395
 RVEDVi, ml3/m281.8 ± 16.279.8 ± 11.60.279
 RVESVi, ml3/m239.3 ± 11.837.4 ± 8.00.073
 RVEF, %53.2 ± 6.255.2 ± 6.80.492
Myocardial tissue characteristics
 T2w ratio1.3 ± 0.51.3 ± 0.40.621
 LGE presence, n(%)7 (25%)7 (25%)1
 LGE extent, %11.8 ± 2.98.1 ± 2.00.239
 Native T1-myo, ms1289 ± 531262 ± 590.013
 T2 mapping-myo, ms44.4 ± 4.041.8 ± 4.20.001
 ECV-myo, %30.7 ± 4.127.6 ± 4.40.001
Skeletal tissue characteristics
 Native T1-sk, ms1268 ± 1031154 ± 73< 0.001
 T2 mapping-sk, ms34.5 ± 3.529.7 ± 2.8< 0.001
 ECV-sk, %29.2 ± 11.121.9 ± 11.20.011
  1. Abbreviations: Hct hematocrit, CRP C-reactive protein, ESR erythrocyte sedimentation rate, CK creatine kinase, CK-MB creatine kinase-MB, TnT troponin T, NT-proBNP N-terminal pro b-type natriuretic peptide, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, LVmassi left ventricular mass index, LVEF left ventricular ejection fraction, RVEDVi right ventricular end-diastolic volume index, RVESVi right ventricular end-systolic volume index, RVEF right ventricular ejection fraction, T2W T2-weighted ratio, LGE late gadolinium enhancement, ECV extracellular volume fraction
  2. Values in bold indicate P values < 0.05
  3. P* value for comparison between baseline and follow-up characteristics among IIM patients